Role of cerebrolysin® in cervical spondylotic myelopathy patients: a prospective randomized study

Publication date: Available online 14 November 2017
Source:The Spine Journal
Author(s): Ahmad Fouad Abdelbaki Allam, Tarek Abdalla Ahmed Abotakia, Wael Koptan
Background ContextCerebrolysin^® is a mixture containing 85% free amino acids and 15% biologically active low-molecular weight peptides, that is believed to mimic the effects of endogenous neurotrophic factors to interact with the pathological process cascade of neurodegenerative diseases. No study has examined the effect of Cerebrolysin^® on the cervical myelopathic patients.PurposeTo evaluate the effect of cerebrolysin^® as a conservative modality on cervical spondylotic myelopathic patients.Study DesignProspective randomized study.Patient Sample192 patients with cervical spondylotic myelopathy (CSM) were subdivided blindly into 2 equal groups.Outcome Measuresfollowed up at 1, 3 and 6 months comparing the recovery rate Japanese orthopaedic association (JOA) score for cervical myelopathy between the two groups.Methodsgroup I received cerebrolysin and group II received placebo for 4 weeks, both groups received celecoxib 200 mg for 4 week.Conflict of interestAll the authors declare that they have no conflict of interest.Funding sourceNo disclosure of funding received for this work from any organization.ResultsMyelopathy improved in 92% and 52% of patients at 1 month in group I and II respectively, these were changed at 6 months to 87% and 33%, the remaining 13 % in group I were not improved nor deteriorated, while in group II 60% not improved nor deteriorated and 7% were deteriorated with statistically significant differences when comparing the mean JOA recovery rates % between the 2 groups at 1, 3 and 6 monthsConclusionCerebrolysin^® over 4 weeks is safe and effective for improvement of cervical spondylotic myelopathy as compared to placebo with no reported cases of neurological deterioration over 6 month follow up.



http://ift.tt/2yDcp33